JADE101 for Berger's Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This Phase 3 study will evaluate the safety and efficacy of JADE101 compared with placebo in adults with immunoglobulin A nephropathy (IgAN). The results will contribute to the overall clinical characterization of JADE101 in this patient population.
Who Is on the Research Team?
Li Li, MD
Principal Investigator
Jade Biosciences
Are You a Good Fit for This Trial?
This trial is for adults diagnosed with IgA nephropathy (Berger's disease) confirmed by kidney biopsy. Participants must have enough protein in their urine, decent kidney function, and be on stable doses of certain blood pressure medicines for at least 12 weeks.Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- JADE101
Trial Overview
The study compares a new drug called JADE101 to a placebo (inactive treatment) to see if it helps people with IgA nephropathy. Participants are randomly assigned to receive either JADE101 or placebo without knowing which one they get.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Placebo Group
Subcutaneous (SC) injection of JADE101 with Q8W maintenance dosing
Subcutaneous (SC) injection of JADE101 with Q12W maintenance dosing
Subcutaneous (SC) injection of placebo during the placebo-controlled treatment period
Find a Clinic Near You
Who Is Running the Clinical Trial?
Jade Biosciences, Inc.
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.